17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In mammalian cells, telomerase transcribes telomeres in large G-rich non-coding RNA, known as telomeric repeat-containing RNA (TERRA), which folds into noncanonical nucleic acid secondary structures called G-quadruplexes (G4s). Since TERRA G4 has been shown to be involved in telomere length and translation regulation, it could provide valuable insight into fundamental biological processes, such as cancer growth, and TERRA G4 binders could represent an innovative strategy for cancer treatment. In this work, the three best candidates identified in our previous virtual screening campaign on bimolecular DNA/RNA G4s were investigated on the monomolecular Tel DNA and TERRA G4s by means of molecular modelling simulations and in vitro and in cell analysis. The results obtained in this work highlighted the stabilizing power of all the three candidates on TERRA G4. In particular, the two compounds characterized by a chromene scaffold were selective TERRA G4 binders, while the compound with a naphthyridine core acted as a dual Tel/TERRA G4-binder. A biophysical investigation by circular dichroism confirmed the relative stabilization efficiency of the compounds towards TERRA and Tel G4s. The TERRA G4 stabilizing hits showed good antiproliferative activity against colorectal and lung adenocarcinoma cell lines. Lead optimization to increase TERRA G4 stabilization may provide new powerful tools against cancer.

          Related collections

          Author and article information

          Contributors
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          (View ORCID Profile)
          Journal
          PHARH2
          Pharmaceuticals
          Pharmaceuticals
          MDPI AG
          1424-8247
          May 2022
          April 28 2022
          : 15
          : 5
          : 548
          Article
          10.3390/ph15050548
          9147070
          35631373
          76bc5a21-ec16-481b-b607-b52eb62100fb
          © 2022

          https://creativecommons.org/licenses/by/4.0/

          History

          Comments

          Comment on this article

          Related Documents Log